Aerovate Therapeutics, Inc.
NASDAQ:AVTE
2.63 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Aerovate Therapeutics, Inc. |
Symbool | AVTE |
Munteenheid | USD |
Prijs | 2.63 |
Beurswaarde | 75,939,935 |
Dividendpercentage | 0% |
52-weken bereik | 1.25 - 32.415 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Timothy P. Noyes M.B.A. |
Website | https://aerovatetx.com |
An error occurred while fetching data.
Over Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)